Key Highlights

● MiMedx reported third-quarter Revenue of $62.28 million against a $68.56 million consensus.

● The shares gapped down and traded near $3.68 on October 29.

● Health care was the best-performing S&P 500 sector, leaving MiMedx out of step.

● Reimbursement policy changes could significantly influence the stock.

MiMedx Group (NASDAQ:MDXG) gapped lower after its third-quarter revenue fell well short of analyst estimates, leaving the wound-care company out of step with Thursday's strong rally in health care stocks.

A gap down after the report

MiMedx Group slid on Thursday, October 29, after reporting third-quarter revenue that missed forecasts by a wide margin. The stock traded at about $3.68 during the session, according to market data, after Gapping down at the open.

The company released its results on Wednesday, October 28. Revenue came in at $62.28 million against a consensus estimate of $68.56 million, according to the same source. That shortfall of more than $6 million is substantial for a company of MiMedx's size, and it set the tone for Thursday's trading.

What MiMedx makes

MiMedx develops and sells products derived from placental tissue, used mainly to help treat chronic wounds such as diabetic foot ulcers and venous leg ulcers, as well as in surgical settings. Its products are sold to hospitals, wound-care clinics and physician offices.

Revenue in this Business depends heavily on reimbursement, the payments that Medicare and private insurers make for the products. Changes in coverage rules or payment rates can quickly affect sales volumes, which makes quarterly results sensitive to policy shifts.

The wrong side of a health care rally

The miss stood out because health care was the best-performing sector in the S&P 500 on Thursday, according to market data. Investors piled into the sector as they rotated out of mega-cap technology.

Eli Lilly (NYSE:LLY) rallied after reporting strong revenue growth and raising its guidance. Merck (NYSE:MRK) climbed after beating forecasts and lifting its outlook. The health care ETF XLV and pharmaceutical ETF IHE both rose at midday, according to media reports. Among smaller names, Glaukos (NYSE:GKOS) and Teladoc (NYSE:TDOC) surged after strong results.

MiMedx did not join the rally. Its revenue miss gave investors a company-specific reason for caution, regardless of sector strength. Iovance Biotherapeutics (NASDAQ:IOVA) was another health care decliner, plunging after updated lung cancer data.

A split market

The broader market was divided. The Russell 2000 rose 28.71 points to close at 2,859.22, while the S&P 500 lost 23.59 points to 7,720.39 and the Nasdaq Composite tumbled 365.13 points to 26,184.72. Alphabet (NASDAQ:GOOGL)'s worst session since its 2004 IPO, which erased roughly $500 billion of market value, drove much of the large-cap weakness.

Breadth was positive. NYSE advancers outnumbered decliners by 1.95 to 1, and more than 400 S&P 500 members closed higher. One Investment strategist told media outlets: "There's plenty of other places to go with your money outside of the AI trade that have pretty decent prospects."

The macro backdrop

Thursday's data showed the economy accelerating. Third-quarter GDP growth beat forecasts and consumer spending held up, according to the government's advance estimate. September PCE Inflation ran hot, however, and the Federal Reserve held rates steady on Wednesday with two officials dissenting in favour of a hike.

For small medical-products companies, higher rates can raise borrowing costs and weigh on valuations, adding to the pressure when results disappoint.

What to watch

Investors will look for details on what caused the revenue shortfall, including whether it reflected reimbursement changes, competitive pressure or timing of orders. Any update to full-year guidance will be closely followed.

Analyst estimate and price-target changes are likely after a miss of this size. Any changes to reimbursement policy for wound-care products could also have a significant influence on the stock. On the macro side, the Fed's December 8–9 decision and Friday's Employment Cost index may shape sentiment toward smaller health care names.